Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

July 31, 2018

Conditions
Cerebral Palsy
Interventions
BIOLOGICAL

sibling umbilical cord blood

All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.

Trial Locations (1)

27705

Duke University Medical Center, Durham

All Listed Sponsors
lead

Joanne Kurtzberg, MD

OTHER

NCT02599207 - Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy | Biotech Hunter | Biotech Hunter